Summary
Over the last 25 years, academic and pharmaceutical research has made significant progress, increasing Hematologic Malignancies (HM) patients’ survival rates and improving quality of life. However, a substantial proportion of patients with HM still have a poor prognosis due...
More information & hyperlinks
Web resources: | https://www.harmony-alliance.eu/ |